BSFAF (BSF Enterprise) Debt-to-Revenue : 10.30 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is BSF Enterprise Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BSF Enterprise's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.10 Mil. BSF Enterprise's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. BSF Enterprise's annualized Revenue for the quarter that ended in Sep. 2024 was $0.01 Mil. BSF Enterprise's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 10.30.

BSF Enterprise Debt-to-Revenue Historical Data

The historical data trend for BSF Enterprise's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BSF Enterprise Debt-to-Revenue Chart

BSF Enterprise Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

12.19

1.34

BSF Enterprise Semi-Annual Data
	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial							N/A	N/A	6.09	1.09	10.30

Competitive Comparison of BSF Enterprise's Debt-to-Revenue

For the Biotechnology subindustry, BSF Enterprise's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BSF Enterprise's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BSF Enterprise's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BSF Enterprise's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

BSF Enterprise Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BSF Enterprise's Debt-to-Revenue for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.103	+	0)	/	0.077
	=	1.34

BSF Enterprise's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.103	+	0)	/	0.01
	=	10.30

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Sep. 2024) Revenue data.

BSF Enterprise Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BSF Enterprise's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BSF Enterprise Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BSF Enterprise PLC (OTCPK:BSFAF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

BSFA:UK

Address

2 Portman Street, London, GBR, W1H 6DU

Website

https://www.bsfenterprise.com

BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.

BSF Enterprise Headlines

From GuruFocus

BSF Enterprise PLC Provides City-MixTM Bio-Pharmaceutical Update

By Marketwired • 07-18-2023